Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
28 Results for "
alternative pathway
" in MedChemExpress (MCE) Product Catalog:
Products (28)
28 Results for "alternative pathway" in MCE Product Catalog:
5
Target:
Research Areas:
Danicopan (ACH-4471), a selective and orally active small-molecule factor D inhibitor, shows high binding affinity to human Factor D with Kd value of 0.54 nM. Danicopan (ACH-4471) inhibits alternative pathway of complement (APC) activity, has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) .
1
Target:
Synonyms: BCX9930
Target:
Research Areas:
Pelecopan (BCX9930) is a potent, selective, orally active inhibitor of complement factor D with an IC50 value of 14.3 nM. Pelecopan can target factor D to prevent both intravascular and extravascular hemolysis in PNH. Pelecopan also be used for other alternative pathway (AP) mediated diseases .
Cat. No.: HY-P99965
CAS No.: 1917321-26-6
Synonyms: SKY59; RO7112689; RG-6107
Target:
Research Areas:
Cat. No.: HY-P990952
CAS No.: 2527079-60-1
Synonyms: OMS906
Target:
Research Areas:
Target:
Research Areas:
FD-IN-1 (Compound 12) is an orally bioavailable and selective factor D (FD) inhibitor with an IC50 of 12 nM. Complement FD, a highly specific S1 serine protease, plays a central role in the alternative complement pathway of the innate immune system. FD-IN-1 also inhibits factor XIa (FXIa) and Tryptase β2 with IC50s of 7.7 and 6.5 µM, respectively .
Cat. No.: HY-P99653A
Synonyms: VAY-736 (FUT8-KO)
Target:
Research Areas:
Cat. No.: HY-P99298
CAS No.: 1278466-20-8
Synonyms: RG 7417; TNX 234; Anti-CFD Recombinant Antibody
Target:
Research Areas:
Cat. No.: HY-158143
CAS No.: 2918814-97-6
Target:
Research Areas:
AZD3470 is an orally active MTA-cooperative PRMT5 inhibitor, selective for MTAP-deficient tumors. AZD3470 induces cell cycle G2/M phase alterations, DNA damage, apoptosis, and symmetric dimethylarginine reduction. AZD3470 alters alternative splicing, increases skipped exon events in DNA repair and cell cycle pathways, and inhibits cancer cell proliferation and tumor growth. AZD3470 can be used for the research of non-small cell lung cancer and MTAP-deleted solid tumors .
Target:
Research Areas:
Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases .
Cat. No.: HY-113405R
CAS No.: 641-77-0
Category:
Cat. No.: HY-141876
CAS No.: 2278356-90-2
Research Areas:
PRT543 is an orally active selective PRMT5 inhibitor. PRT543 reduces intracellular symmetric dimethylarginine (sDMA) levels, downregulates the expression of genes related to DNA damage repair and DNA replication pathways, and induces abnormal alternative splicing. PRT543 inhibits the MYB, NOTCH1 and PI3K/AKT signaling pathways, promotes nuclear translocation of FOXO1, upregulates the pro-apoptotic protein BAX, and enhances cellular sensitivity to BCL-2 inhibition. PRT543 disrupts the normal RNA splicing process and exerts a synthetic lethal effect on myeloid tumor cells carrying splicing factor mutations. PRT543 can be used in research related to various cancers including breast cancer, ovarian cancer and acute myeloid leukemia .
Cat. No.: HY-N12265
CAS No.: 108885-62-7
Category:
Human Gut Microbiota Metabolites Viola philippica Cav. Microorganisms Terpenoids Sesquiterpenes Violaceae Extract Plants Endogenous metabolite
Target:
Cat. No.: HY-161239
Target:
Research Areas:
(S)-IB-96212 (compound 4), an oligomycin derivative, inhibits the MurD2 reaction, but not the MurL reaction. (S)-IB-96212 is a specific inhibitor of the alternative pathway of peptidoglycan biosynthesis. (S)-IB-96212 weakly inhibits the MurD reaction .
Cat. No.: HY-N7241
CAS No.: 94978-16-2
Target:
Cat. No.: HY-W016628R
CAS No.: 1128-23-0
Synonyms: L-Gulonolactone (Standard)
Cat. No.: HY-113405S
Cat. No.: HY-P992456
Target:
Research Areas:
SAR-443809 is a monoclonal antibody targeting complement factor Bb that inhibits the alternative complement pathway. SAR-443809 blocks the cleavage of C3 and factor B via selective binding to the activated form factor Bb, with a KD of 7.3 nM for human factor Bb. SAR-443809 inhibits the amplification loop of the alternative complement pathway and C3 activation, reduces C3b deposition, and blocks the activation of pathways associated with intravascular and extravascular hemolysis. SAR-443809 can be used for research on hematological and renal disorders mediated by abnormal alternative complement pathway activity .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
